Search Medical Condition
Please enter condition
Please choose location from dropdown

Ota-city, Japan Clinical Trials

A listing of Ota-city, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (422) clinical trials

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

The total study duration per patient is expected to be up to 68 weeks that will consist of a 4-week run-in period, 52-week treatment period, and a 12-week posttreatment period.

Phase

0.0 miles

Learn More »

Long-term Study of Lemborexant in Insomnia Disorder

This is a long-term (approximately 1 year), multicenter, randomized, controlled, double-blind, parallel group study of two doses of lemborexant and placebo in approximately 900 male or female participants with insomnia disorder. Approximately 40% of participants will be age 65 years or older. The study will last a maximum of 60 ...

Phase

0.0 miles

Learn More »

Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

The purpose of this study is to assess the efficacy and safety of the intravenous drip infusion of ART-123 in patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF) in a multicenter, double-blind, randomized, placebo-controlled, parallel group comparison study, and to confirm its superiority over placebo with survival rate on ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

The maximum study duration per patient will be approximately 41 weeks: an up to 14-week screening period (consisting of an up to 2-week screening phase and a 12-week run-in phase), a 26-week randomized treatment period, and a 3-day post-treatment safety follow-up period.

Phase

0.0 miles

Learn More »

A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

This is a phase 3, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics of long-term administration of TAK-536 once daily for 52 weeks in pediatric patients aged 6 to less than 16 years with hypertension. The study consists of a 2-week Run-in Period, a 52-week Treatment Period (Treatment ...

Phase

0.0 miles

Learn More »

Study of ONO-8577 in Patients With Overactive Bladder

The objective of the study is to evaluate the efficacy and safety of ONO-8577 compared to combination of solifenacin succinate and mirabegron or placebo for overactive bladder

Phase

0.0 miles

Learn More »

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer

The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-nave subjects with stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation ...

Phase

0.0 miles

Learn More »

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

The primary objective of this study is to investigate the effect of 5 mg KHK2375 on progression free survival (PFS) when administered orally at weekly intervals in combination with exemestane in a placebo-controlled, double-blind comparative study in subjects with advanced or recurrent hormone receptor-positive breast cancer. The secondary objectives are ...

Phase

0.0 miles

Learn More »

Diffusion-Weighted MRI for Liver Metastasis

The advancements of systemic and local therapies for complex CRLM have led to the increased incidence of DLMs. It is hypothesized that DW-MRI imaging could distinguish between a metastasis not completely sterilized by conversion therapy and a sterilized scar (non-viable tumor). If this can be demonstrated, the use of DW-MRI ...

Phase N/A

0.0 miles

Learn More »

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

A screening period, up to 3 weeks, will apply only for patients coming from DRI12544 study. The total study duration, per patient, is a maximum of 108 weeks (or 111 weeks considering a maximum screening period of 3 weeks for Study DRI12544) for the patients enrolled prior to Amendment 04 ...

Phase

0.0 miles

Learn More »